Comparison of PSA Values of Prostate Cancer Patients Before, During and After Prostate Biopsy Using Gleason Score Mehmet KILINC1, Yunus Emre GOGER1, Hasan.

Slides:



Advertisements
Similar presentations
Introduction The incidence of prostate cancer in Asians is lower compared to the Westerners in men with PSA
Advertisements

THE CLINICO-PATHOLOGIC PATTERNS OF PROSTATIC DISEASES AND PROSTATE CANCER IN SAUDI PATIENTS Hisham A. M. Mosli, FRCSC, FACS Taha A. Abdel-Meguid, MD Jaudah.
EXTRAPERITONEAL RADICAL PROSTATECTOMY AND PREVIOUS HISTORY OF HERNIA REPAIR: EVALUATION OF RESULTS SELCUK KESKIN, GUILLAUME GUICHARD, ÁNDRAS HOZNEK, ALEXANDRE.
High-grade Prostatic Intraepithelial Neoplasia on Needle Biopsy Risk of Cancer on Repeat Biopsy Related to Number of Involved Cores and Morphologic Pattern.
Prostate Needle Biopsy: The Pitfalls and the Role of the Pathologist – Patient Track Prostate Cancer Symposium “Intriguing Cases / Emerging Strategies.
Steven Joniau Filip Ameye
RISK OF NON SIGNIFICANT PROSTATE CANCER IN PROSTATE CANCER PATIENTS DIAGNOSED BY AN EXTENDED PROSTATE NEEDLE BIOPSY PROCEDURE AND TREATED BY RADICAL PROSTATECTOMY.
Surrogate End point for Prostate Cancer- Specific Mortality After RP or EBRT A D’Amico J Nat Ca Inst 95,
Dan Spratt, MD Department of Radiation Oncology Neuroendocrine Prostate Cancer: FDG-PET and Targeted Molecular Imaging.
Prostate Cancer: A Case for Active Surveillance Philip Kantoff MD Dana-Farber Cancer Institute Professor of Medicine Harvard Medical School.
The PCA3 Assay improves the prediction of initial biopsy outcome and may be indicative of prostate cancer aggressiveness de la Taille A, Irani J, Graefen.
Routine PSA: Evaluating the Evidence Sheldon Greenfield, MD Health Policy Research Institute University of California, Irvine October 23, 2012.
Prevention with Finasteride Ian M. Thompson, MD October, 2009.
POTENTIAL FOR FAILURE OF FOCAL PROSTATE HEMI-ABLATION STRATEGIES PG O’Malley 1, B Al Hussein Al Awamlh 1, AM Sarkisian 1, DP Nguyen 1, S Jin 1, R Lee 1,
INCREASED EXPRESSION OF PROTEIN KINASE CK2  SUBUNIT IN HUMAN GASTRIC CARCINOMA Kai-Yuan Lin 1 and Yih-Huei Uen 1,2,3 1 Department of Medical Research,
Prostate Cancer: Treatment choices Prostate Cancer: Treatment choices Winston W Tan MD FACP Winston W Tan MD FACP Senior Consultant Senior Consultant Genitourinary.
FREEDOM FROM PROGRESSION FOR PATIENTS RECEIVING I 125 VERSUS Pd 103 FOR PROSTATE BRACHYTHERAPY Jane Cho, Carol Morgenstern, Barbara Napolitano, Lee Richstone,
Understanding Prostate Myths
South West Public Health Observatory The changing casemix of prostate cancer patients and prostatectomies in the South West Sean McPhail.
Date of download: 6/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Comparison of MR/Ultrasound Fusion–Guided Biopsy With.
Nutrition2000.com. Prostate Cancer Treatment Protocol Prostate cancer should not be neglected anymore as it might put the life of your spouse, father.
International Neurourology Journal 2015;19:
#4826 Cancer/testis antigen expression pattern is a potential biomarker for prostate cancer aggressiveness Luciane T. Kagohara1, Prakash Kulkarni1, Takumi.
Prostate Cancer Screening in the fit Chilean Elderly: a head to head comparison of total serum PSA versus age adjusted PSA versus primary circulating prostate.
Dr. Zeynep Altuntaş Necmettin Erbakan University Konya , TURKEY
Active Surveillance for Prostate Cancer: A preliminary look at the use of multi-parametric-MRI and cancer genomics for candidate disease monitoring Rafael.
Volume 155, Issue 3, Pages (March 1996)
* Potential use of HP and AMBP in urine for the screening of prostate cancer Sanja Kiprijanovska1, Selim Komina2, Gordana Petrusevska2,
74-year-old man with stage T2a Gleason score prostate cancer (prostate specific antigen = ng/mL) in right transition zone (TZ) with history.
The PSA Era is not Over for Prostate Cancer
Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH): More Than Treating Symptoms?  Mark J. Speakman  European Urology Supplements 
FACTORS RELATED WITH URINARY INCONTINENCE GRADE AFTER RADICAL PROSTATECTOMY Padilla Fernández, B.1; Virseda Rodríguez, ÁJ2; Pereira, BJ3, Coelho, H4,;
International Neurourology Journal 2016;20:
Prevention of Prostate Cancer. Fact or Fiction?
The Value of Contrast-Enhanced Ultrasonography Combined with Real-Time Strain Elastography in the Early Diagnosis of Prostate Cancer Chang Ying 1 ;Yang.
International Neurourology Journal 2012;16:
International Neurourology Journal 2013;17:73-77
Patterns of prostate cancer according to the 2005 International Society of Urological Pathology Consensus Conference on Gleason system. (Adapted with permission.
Evaluating Residents’ Medical Knowledge
PHQ2 Screening Negative PHQ2 Screening Positive
Prostate Cancer: Highlights from 2006
European Urology Oncology
Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH): More Than Treating Symptoms?  Mark J. Speakman  European Urology Supplements 
Prostate Cancer Screening- Update
Volume 60, Issue 5, Pages (November 2011)
EVALUATING THE EARLY EFFECTS OF TRU-CUT BIOPSY UNDER CT GUIDANCE IN PATIENTS WITH LUNG TUMOUR AT NATIONAL LUNG HOSPITAL. Dr. Phuong Ngoc Anh National Lung.
Ongoing Gleason Grade Migration in Localized Prostate Cancer and Implications for Use of Active Surveillance  Adam B. Weiner, Ruth Etzioni, Scott E. Eggener 
Volume 62, Issue 1, Pages (July 2012)
Volume 68, Issue 3, Pages (September 2015)
Volume 56, Issue 2, Pages (August 2009)
Volume 63, Issue 6, Pages (June 2013)
Volume 54, Issue 2, Pages (August 2008)
The PSA Era is not Over for Prostate Cancer
Volume 66, Issue 5, Pages (November 2014)
External Beam Radiotherapy as Curative Treatment of Prostate Cancer
Volume 58, Issue 1, Pages (July 2010)
European Urology Oncology
Prostate Cancer Nomograms: An Update
What's New in Prostate Cancer: Highlights from Urologic and Oncologic Congresses in 2006  Michel Soulié, Nicolas Mottet, Laurent Salomon, Jacques Irani,
Trend of Adverse Stage Migration in Patients Treated with Radical Prostatectomy for Localized Prostate Cancer  Felix Preisser, Michele Marchioni, Sebastiano.
Volume 67, Issue 4, Pages (April 2005)
Fernando P. Secin, Fernando J. Bianco, Nicholas T
Difference between the groups
Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH): More Than Treating Symptoms?  Mark J. Speakman  European Urology Supplements 
Guru Sonpavde, MD, Teresa G. Hayes, MD  Mayo Clinic Proceedings 
Study overview. Study overview. A, Schematic illustrating clinical trial design and the nature and number of tissue specimens available for downstream.
Extraction diagram of candidate genes identified by global expression analysis. Extraction diagram of candidate genes identified by global expression analysis.
PSMA expression in pre- and posttreatment prostate carcinoma serum.
Scatterplots and Two-Way Tables
A, TSG-6 staining in human prostate.
Presentation transcript:

Comparison of PSA Values of Prostate Cancer Patients Before, During and After Prostate Biopsy Using Gleason Score Mehmet KILINC1, Yunus Emre GOGER1, Hasan ESEN2 , Ahmet OZTURK1 , Mehmet BALASAR1 1-Konya Necmettin Erbakan University Meram Medical Faculty Department of Urology TURKEY 2-Konya Necmettin Erbakan University Meram Medical Faculty Department of Pathology TURKEY Table 1. PSA1, PSA2, PSA3, PSA4, PSA5 Levels According to Groups Introduction: The prostate specific antigen (PSA) levels of prostate cancer patients have been measured before, during, and after prostate biopsy. We studied the reaction of cancerous prostate tissue to the changes in PSA levels. Material and Method: In the present study 151 patients who underwent prostate biopsy with TRUSG and had prostate cancer according to pathology results were evaluated. The prostate specific antigen levels were measured right after (PSA2, PSA3), 30 minutes (PSA4), and 24 hours (PSA5) following an intervention to the right and left lobes of the prostate. The pathologic specimen obtained during the biopsy was categorized according to Gleason Grading System. Hence four groups were formed. Group 1 consisted of the tissue scored as under 6, group 2 as 6, group 3 as 7, group 4 as above 7 (Table 1). PSA1, PSA2, PSA3, PSA4, and PSA5 levels of the patients were compared according to their groups. Intergroup changes have been measures in pairs using paired difference test. The relation between changes in measured groups and relation between Gleason Score were compared (Table 2). Results: PSA1, PSA2, PSA3, PSA4, and PSA5 levels of 151 prostate cancer patients have been measured. Whereas there was not any statistically significant difference among the PSA2-PSA4 pair (p>0.05), there was a significant difference in PSA1-PSA2, PSA1-PSA3, PSA1-PSA4, PSA1-PSA5, PSA2PSA3, PSA2-PSA5, PSA3-PSA4, PSA3-PSA5, PSA4-PSA5 pairs (p<0.05). In the groups categorized according to Gleason Grading System, the higher Gleason score was the less was the statistically meaningful difference among the groups. In both group 1 and 2, there was not any statistically significant difference among the PSA2-PSA4 pair likewise in the PSA3-PSA4 pair in group 3, and PSA2-PSA5 in group 4. The higher the Gleason score was the closer were the increase ratio in PSA2, PSA3, PSA4, and PSA5 levels. Table 2. Statistical Analysis of PSA Measured Pairs According to Groups Conclusions: Despite the increase in PSA levels with the increase in Gleason Score, the difference among the measures PSA pairs decreased. The higher the prostate cancer grade became, the lower did PSA secretion sank. In prostate cancer patients with close scores for measured pairs, Gleason score can also be considered to be high in actual clinical use.